Detalles de la búsqueda
1.
A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.
Breast Cancer Res Treat
; 189(2): 411-423, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34302589
2.
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.
Nat Commun
; 15(1): 2446, 2024 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38503755
3.
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma.
Nat Med
; 27(2): 289-300, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33495604
4.
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer.
Clin Cancer Res
; 26(22): 5974-5989, 2020 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32723837
5.
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Cancer Discov
; 10(8): 1174-1193, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32404308
6.
High levels of RNA-editing site conservation amongst 15 laboratory mouse strains.
Genome Biol
; 13(4): 26, 2012 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-22524474
Resultados
1 -
6
de 6
1
Próxima >
>>